A Meta-Analysis of Myopia Control with MiSight 1 Day Contact Lenses

Abstract

The purpose of this research (PROSPERO Registration No. CRD42023396866) is to evaluate efficacy of MiSight 1 Day Contact Lenses (CooperVision) for controlling myopia progression. Data were researched from search in PubMed, MEDLINE, EMBASE, Web of Science and Cochrane Library ended on February 3, 2023. Our meta-analyses included three RCTs and one retrospective study and covered 470 eyes which have tested the efficacy of MiSight. The research results include the changes of refractive errors (spherical equivalent refraction) and axial length from the beginning of intervention to the end of follow-up. The weighted mean difference (WMD) of the change of spherical equivalent refraction (SER) in MiSight groups and control groups were 0.098D (95% CI, 0.006-0.189, p = 0.037) in 6 months, 0.353D (95% CI, 0.261-0.445, p < 0.0001) in 12 months and 0.432D (95% CI, 0.181-0.683, p = 0.001) in 24 months. The weighted mean difference (WMD) of change of axial length (AL) in MiSight groups and control group were 0.098D (95% CI, 0.006-0.189, p = 0.037) in 6 months, 0.353D (95% CI, 0.261-0.445, p < 0.0001) in 12 months and 0.432D (95% CI, 0.181-0.683, p = 0.001) in 24 months. This meta-analysis suggests that MiSight is effectual on Myopia control.